Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00067041 · ClinicalTrials.gov registry record · Phase 2
Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft
A Phase 2 study, sponsored by United Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00067041 is a Phase 2 study that was terminated before completion, run by United Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT00067041, a Phase 2 study, was terminated before completion, sponsored by United Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Approximately 30 patients will be enrolled in this 12-week study designed to assess the effect of continuous subcutaneous Remodulin therapy on the outcome of infrainguinal bypass grafts in patients with critical limb ischemia (CLI). Portions of the study will be conducted in the hospital and on an out-patient basis. The study will be conducted at multiple centers.
Interventions
- DRUG Remodulin (treprostinil sodium) Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-03 |
| Est. Completion | 2003-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00067041
The ClinicalTrials.gov registry entry for NCT00067041 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Remodulin (treprostinil sodium) Injection is the first listed.
NCT00067041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00067041 about?
NCT00067041 is a clinical study titled "Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft". Approximately 30 patients will be enrolled in this 12-week study designed to assess the effect of continuous subcutaneous Remodulin therapy on the outcome of infrainguinal bypass grafts in patients with critical limb ischemia (CLI). Portions of the study will be conducted in the hospital and on an o...
What is the current status of trial NCT00067041?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2003-03. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00067041?
The interventions under investigation include: Remodulin (treprostinil sodium) Injection (DRUG).
Who is sponsoring clinical trial NCT00067041?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.